The groundbreaking research of NOMIS Distinguished Scientist Awardee Don W. Cleveland is the subject of Swiss newspaper the Tages Anzeiger’s article “Der Bändiger von schweren Hirnleiden” (“The tamer of severe brain disorders”). Cleveland developed gene-silencing therapies, called designer DNA drugs, which he demonstrated can significantly slow the progression of ALS (amyotrophic lateral sclerosis) in mice. The designer DNA drugs are being tested in clinical trials to treat neurodegenerative diseases such as ALS, Huntington’s disease, Alzheimer’s or frontotemporal dementia.
NOMIS is supporting Cleveland’s research project, Mechanisms of Gene Silencing and Liquid-Liquid De-mixing in the Nervous System.
Don W. Cleveland
Head of the Laboratory for Cell Biology at the Ludwig Institute for Cancer Research
Ludwig Cancer Research
Mechanisms of Gene Silencing and Liquid-Liquid De-mixing in the Nervous System
NOMIS RESEARCH PROJECT